CN102048701B - 一种匹伐他汀钙肠溶缓释微丸制剂及其制备方法 - Google Patents
一种匹伐他汀钙肠溶缓释微丸制剂及其制备方法 Download PDFInfo
- Publication number
- CN102048701B CN102048701B CN 201010581413 CN201010581413A CN102048701B CN 102048701 B CN102048701 B CN 102048701B CN 201010581413 CN201010581413 CN 201010581413 CN 201010581413 A CN201010581413 A CN 201010581413A CN 102048701 B CN102048701 B CN 102048701B
- Authority
- CN
- China
- Prior art keywords
- enteric
- pitavastatin calcium
- layer
- slow release
- release
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- RHGYHLPFVJEAOC-FFNUKLMVSA-L pitavastatin calcium Chemical compound [Ca+2].[O-]C(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1.[O-]C(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 RHGYHLPFVJEAOC-FFNUKLMVSA-L 0.000 title claims abstract description 48
- 229960003296 pitavastatin calcium Drugs 0.000 title claims abstract description 48
- 238000002360 preparation method Methods 0.000 title claims abstract description 42
- 238000013268 sustained release Methods 0.000 title claims abstract description 33
- 239000012730 sustained-release form Substances 0.000 title claims abstract description 33
- 239000006187 pill Substances 0.000 claims abstract description 40
- 239000010410 layer Substances 0.000 claims abstract description 33
- 239000012055 enteric layer Substances 0.000 claims abstract description 18
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 39
- 239000008188 pellet Substances 0.000 claims description 29
- 238000000576 coating method Methods 0.000 claims description 26
- 239000011248 coating agent Substances 0.000 claims description 24
- 238000007789 sealing Methods 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 17
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 17
- 230000001476 alcoholic effect Effects 0.000 claims description 14
- 239000012530 fluid Substances 0.000 claims description 14
- 239000003361 porogen Substances 0.000 claims description 14
- 229920002472 Starch Polymers 0.000 claims description 10
- 239000011230 binding agent Substances 0.000 claims description 10
- 239000004014 plasticizer Substances 0.000 claims description 10
- 239000008107 starch Substances 0.000 claims description 10
- 235000019698 starch Nutrition 0.000 claims description 10
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 9
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 9
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 9
- NIQCNGHVCWTJSM-UHFFFAOYSA-N Dimethyl phthalate Chemical compound COC(=O)C1=CC=CC=C1C(=O)OC NIQCNGHVCWTJSM-UHFFFAOYSA-N 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 239000007921 spray Substances 0.000 claims description 8
- 239000004925 Acrylic resin Substances 0.000 claims description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 7
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 7
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 7
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 7
- 239000000741 silica gel Substances 0.000 claims description 7
- 229910002027 silica gel Inorganic materials 0.000 claims description 7
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 6
- 229930006000 Sucrose Natural products 0.000 claims description 6
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims description 6
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 6
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 6
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 6
- 239000005720 sucrose Substances 0.000 claims description 6
- 239000001069 triethyl citrate Substances 0.000 claims description 6
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims description 6
- 235000013769 triethyl citrate Nutrition 0.000 claims description 6
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 6
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 claims description 5
- 239000001354 calcium citrate Substances 0.000 claims description 5
- 235000002639 sodium chloride Nutrition 0.000 claims description 5
- 239000006188 syrup Substances 0.000 claims description 5
- 235000020357 syrup Nutrition 0.000 claims description 5
- 235000013337 tricalcium citrate Nutrition 0.000 claims description 5
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 claims description 4
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 claims description 4
- FBSAITBEAPNWJG-UHFFFAOYSA-N dimethyl phthalate Natural products CC(=O)OC1=CC=CC=C1OC(C)=O FBSAITBEAPNWJG-UHFFFAOYSA-N 0.000 claims description 4
- 229960001826 dimethylphthalate Drugs 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 4
- 229960003943 hypromellose Drugs 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- 239000004375 Dextrin Substances 0.000 claims description 3
- 229920001353 Dextrin Polymers 0.000 claims description 3
- 239000001856 Ethyl cellulose Substances 0.000 claims description 3
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- 229920002301 cellulose acetate Polymers 0.000 claims description 3
- 235000019425 dextrin Nutrition 0.000 claims description 3
- 229920001249 ethyl cellulose Polymers 0.000 claims description 3
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 3
- 238000001125 extrusion Methods 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 235000001727 glucose Nutrition 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 210000003516 pericardium Anatomy 0.000 claims description 3
- 229910000160 potassium phosphate Inorganic materials 0.000 claims description 3
- 235000011009 potassium phosphates Nutrition 0.000 claims description 3
- 238000005096 rolling process Methods 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 239000000600 sorbitol Substances 0.000 claims description 3
- 238000005507 spraying Methods 0.000 claims description 3
- 235000000346 sugar Nutrition 0.000 claims description 3
- 206010008190 Cerebrovascular accident Diseases 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 2
- 239000004141 Sodium laurylsulphate Substances 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 2
- QXDHJHQRJCJRAU-UHFFFAOYSA-N calcium;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Ca].OC(=O)CC(O)(C(O)=O)CC(O)=O QXDHJHQRJCJRAU-UHFFFAOYSA-N 0.000 claims description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 2
- 239000005038 ethylene vinyl acetate Substances 0.000 claims description 2
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims description 2
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims description 2
- 238000005457 optimization Methods 0.000 claims description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 2
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 claims description 2
- -1 polydimethylsiloxane Polymers 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 23
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 20
- 229940079593 drug Drugs 0.000 abstract description 15
- 235000012000 cholesterol Nutrition 0.000 abstract description 9
- 239000008280 blood Substances 0.000 abstract description 7
- 210000004369 blood Anatomy 0.000 abstract description 7
- 238000005516 engineering process Methods 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 6
- 210000004051 gastric juice Anatomy 0.000 abstract description 4
- 230000001603 reducing effect Effects 0.000 abstract description 4
- 239000002253 acid Substances 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000007888 film coating Substances 0.000 abstract 1
- 238000009501 film coating Methods 0.000 abstract 1
- 238000002955 isolation Methods 0.000 abstract 1
- 229940124531 pharmaceutical excipient Drugs 0.000 abstract 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 15
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 15
- 229920003136 Eudragit® L polymer Polymers 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 230000006399 behavior Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000007779 soft material Substances 0.000 description 3
- 229920000178 Acrylic resin Polymers 0.000 description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 206010013710 Drug interaction Diseases 0.000 description 1
- 208000000857 Hepatic Insufficiency Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 1
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 229920002535 Polyethylene Glycol 1500 Polymers 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 description 1
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- IQSHMXAZFHORGY-UHFFFAOYSA-N methyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound COC(=O)C=C.CC(=C)C(O)=O IQSHMXAZFHORGY-UHFFFAOYSA-N 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
Images
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201010581413 CN102048701B (zh) | 2010-11-29 | 2010-11-29 | 一种匹伐他汀钙肠溶缓释微丸制剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201010581413 CN102048701B (zh) | 2010-11-29 | 2010-11-29 | 一种匹伐他汀钙肠溶缓释微丸制剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102048701A CN102048701A (zh) | 2011-05-11 |
CN102048701B true CN102048701B (zh) | 2013-01-09 |
Family
ID=43953725
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201010581413 Expired - Fee Related CN102048701B (zh) | 2010-11-29 | 2010-11-29 | 一种匹伐他汀钙肠溶缓释微丸制剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102048701B (zh) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102406656A (zh) * | 2011-11-21 | 2012-04-11 | 南开大学 | 碳酸氢钠肠溶片及制备方法 |
CN103381268B (zh) * | 2012-05-04 | 2017-12-08 | 江苏豪森药业集团有限公司 | 包含质子泵抑制剂的固体药物组合物 |
CN103142552A (zh) * | 2013-02-22 | 2013-06-12 | 广州科的信医药技术有限公司 | 一种洛伐他汀肠溶缓释微丸胶囊及其制备方法 |
CN105412904A (zh) * | 2014-06-17 | 2016-03-23 | 深圳翰宇药业股份有限公司 | 利那洛肽肠溶缓释微丸胶囊制剂及其制备方法和用途 |
CN105268091B (zh) * | 2015-09-18 | 2018-06-22 | 潍坊医学院附属医院 | 妇科防脱落施药装置 |
CN107823181A (zh) * | 2017-12-13 | 2018-03-23 | 合肥凯石医药科技有限公司 | 一种稳定的瑞舒伐他汀钙肠溶微丸及其制备方法 |
CN114272385B (zh) * | 2021-12-30 | 2023-11-14 | 北京英茂药业有限公司 | 一种靶向释放薄膜包衣预混剂及其应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1905880A (zh) * | 2003-11-26 | 2007-01-31 | 诺瓦提斯公司 | 包含有机化合物的组合物 |
-
2010
- 2010-11-29 CN CN 201010581413 patent/CN102048701B/zh not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1905880A (zh) * | 2003-11-26 | 2007-01-31 | 诺瓦提斯公司 | 包含有机化合物的组合物 |
Also Published As
Publication number | Publication date |
---|---|
CN102048701A (zh) | 2011-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102048701B (zh) | 一种匹伐他汀钙肠溶缓释微丸制剂及其制备方法 | |
AU2021282393B2 (en) | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof | |
JP5903522B1 (ja) | 過活動膀胱の治療のための医薬製剤 | |
UA112632C2 (uk) | Дозована форма з модифікованим вивільненням фебуксостату (варіанти) | |
CN101703513B (zh) | 阿司匹林和氯吡格雷或其药学上可接受的盐的复方缓释制剂 | |
IL131308A (en) | Forms of azithromycin with controlled release | |
CN101502491B (zh) | 一种地红霉素肠溶制剂 | |
CN104814923B (zh) | 一种盐酸坦洛新缓释制剂及其制备方法和其应用 | |
CN100376230C (zh) | 择时缓释微丸及其制剂 | |
CN101095681A (zh) | 盐酸阿夫唑嗪渗透泵型控释制剂及其制备方法 | |
CN103550183B (zh) | 一种盐酸曲美他嗪渗透泵控释片及其制备方法 | |
PL192648B1 (pl) | Preparat farmaceutyczny o kontrolowanym uwalnianiu, zawierający inhibitor ACE jako substancję aktywną | |
CN100571703C (zh) | 曲美他嗪缓释微丸及其制备方法 | |
CN101874783A (zh) | 一种含有褪黑素的缓释制剂及其制备方法 | |
EP1839649A1 (en) | Coated formulations for tolterodine | |
CN101120931A (zh) | 一种苯扎贝特缓释组合物 | |
CN102764243B (zh) | 一种阿司匹林脉冲释放微丸和其制剂及其制备方法 | |
CN102247366B (zh) | 包括依那普利和非洛地平的药物组合物缓释制剂 | |
CN105769773A (zh) | 洛索洛芬钠缓释微丸 | |
CN101773482B (zh) | 一种三段式脉冲释药控释片及其制备方法 | |
CN105431140A (zh) | 含有缓释二甲双胍和速释HMG-CoA还原酶抑制剂的复合制剂 | |
CN104856971B (zh) | 一种脉冲双释放制剂及其制备方法与应用 | |
NZ537408A (en) | Microcapsules for the delayed, controlled release of perindopril | |
CN100563636C (zh) | 阿西美辛缓释制剂及制备方法 | |
CN101219118B (zh) | 一种脉冲释放口服药物制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: QINGDAO HANHE PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: QINGDAO HUANGHAI PHARMACEUTICAL CO., LTD. Effective date: 20130307 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C53 | Correction of patent for invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Niu Baihui Inventor after: Cao Ruishan Inventor after: Li Zhenxia Inventor after: Wang Fang Inventor after: Xu Xiaolin Inventor after: Liu Qichang Inventor before: Niu Baihui Inventor before: Cao Ruishan Inventor before: Li Zhenxia Inventor before: Wang Fang Inventor before: Xu Xiaolin |
|
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 266101 QINGDAO, SHANDONG PROVINCE TO: 266102 QINGDAO, SHANDONG PROVINCE Free format text: CORRECT: INVENTOR; FROM: NIU BAIHUI CAO RUISHAN LI ZHENXIA WANG FANG XU XIAOLIN TO: NIU BAIHUI CAO RUISHAN LI ZHENXIA WANG FANG XU XIAOLIN LIU QICHANG |
|
TR01 | Transfer of patent right |
Effective date of registration: 20130307 Address after: Laoshan District Shazikou Street office in Shandong Province, Qingdao City, 266102 Chinese Village Patentee after: Qingdao Hanhe Pharmaceutical Co., Ltd. Address before: 266101 Shandong Province, Qingdao city Laoshan District Four Keyuan Road No. 17 Patentee before: Qingdao Huanghai Pharmaceutical Co., Ltd. |
|
C56 | Change in the name or address of the patentee |
Owner name: QINGDAO HUAHAI PHARMACEUTICAL RESEARCH INSTITUTE C Free format text: FORMER NAME: QINGDAO HANHE PHARMACEUTICAL CO., LTD. |
|
CP03 | Change of name, title or address |
Address after: 266101 Shandong Province, Qingdao city Laoshan District Road No. 17 Keyuan four Building No. 3 Patentee after: QINGDAO HUAHAI PHARMACEUTICAL RESEARCH INSTITUTE CO., LTD. Address before: Laoshan District Shazikou Street office in Shandong Province, Qingdao City, 266102 Chinese Village Patentee before: Qingdao Hanhe Pharmaceutical Co., Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130109 Termination date: 20161129 |